Designer lipids for drug delivery: From heads to tails

Journal of Controlled Release

Volumn 190, Issue , 2014, Pages 274-287

  Kohli, Aditya G ^a,b   Kierstead, Paul H ^c   Venditto, Vincent J ^b   Walsh, Colin L ^a,b   Szoka, Francis C ^a,b  

^a University of California at Berkeley   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Biophysics; Immunology; Liposomes; Payload release; Targeting

Indexed keywords

BIOPHYSICS; CHEMICAL BONDS; DRUG DELIVERY; IMMUNOLOGY; LIPOSOMES;

DESIGN CONSIDERATIONS; DRUG RELEASE PROPERTIES; INTER-MOLECULAR FORCES; MACROSCOPIC BEHAVIORS; PAYLOAD RELEASE; PHYSICOCHEMICAL PROPERTY; TARGETED DRUG DELIVERY; TARGETING;

LIPIDS;

CARDIOLIPIN; CERAMIDE; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; GANGLIOSIDE GM1; LIPID; LIPOSOME; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLINOSITOL; PHOSPHOLIPID; PHOSPHORYL LIPID A; POLYVINYL ALCOHOL; POVIDONE; SULFATIDE; VINCRISTINE SULFATE; DELAYED RELEASE FORMULATION; POLYMER;

ADSORPTION; ANTIGEN PRESENTING CELL; B LYMPHOCYTE ACTIVATION; BIOPHYSICS; CIRCULATION TIME; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG PENETRATION; DRUG RETENTION; DRUG SAFETY; HISTOCOMPATIBILITY COMPLEX; HUMAN; HUMORAL IMMUNITY; HYDROGEN BOND; LIPID MEMBRANE; MOLECULAR INTERACTION; NONHUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; REVIEW; STATIC ELECTRICITY; T LYMPHOCYTE ACTIVATION; VISCOSITY; CHEMICAL PHENOMENA; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG DESIGN; DRUG STABILITY;

DELAYED-ACTION PREPARATIONS; DRUG DESIGN; DRUG STABILITY; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; LIPIDS; LIPOSOMES; POLYMERS;

EID: 84906781757     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2014.04.047     Document Type: Review

References (166)

1. E. Fahy, S. Subramaniam, H.A. Brown, C.K. Glass, A.H. Merrill, and R.C. Murphy et al. A comprehensive classification system for lipids J. Lipid Res. 46 2005 839 861
2. M. Caffrey LIPIDAT: A Database of Thermo Data and Association Information on Lipid Mesomorphic and Polymorphic Transitions 1993 CRC Press
3. L. Bildstein, C. Dubernet, and P. Couvreur Prodrug-based intracellular delivery of anticancer agents Adv. Drug Deliv. Rev. 63 2011 3 23
4. S. Mukherjee, and F. Maxfield Role of membrane organization and membrane domains in endocytic lipid trafficking Traffic 1 2000 203 211
5. H. Lv, S. Zhang, B. Wang, S. Cui, and J. Yan Toxicity of cationic lipids and cationic polymers in gene delivery J. Control. Release 114 2006 100 109 (Pubitemid 44128621)
6. L.H. Reddy, and P. Couvreur Macromolecular Anticancer Therapeutics 2010 Springer
7. Y. Tan, and L. Huang Overcoming the inflammatory toxicity of cationic gene vectors J. Drug Target. 10 2002 153 160 (Pubitemid 34272383)
8. R. Duncan, and R. Gaspar Nanomedicine(s) under the microscope Mol. Pharm. 8 2011 2101 2141
9. L.D. Mayer, M.B. Bally, and P.R. Cullis Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient Biochim. Biophys. Acta Biomembr. 857 1986 123 126 (Pubitemid 16085119)
10. D.C. Drummond, O. Meyer, K. Hong, D.B. Kirpotin, and D. Papahadjopoulos Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors Pharmacol. Rev. 51 1999 691 743
11. R. Kanasty, J.R. Dorkin, A. Vegas, and D. Anderson Delivery materials for siRNA therapeutics Nat. Mater. 12 2013 967 977
12. M.G. Stanton, and S.L. Colletti Medicinal chemistry of siRNA delivery J. Med. Chem. 53 2010 7887 7901
13. T.M. Allen, and C. Hansen Pharmacokinetics of stealth versus conventional liposomes: effect of dose Biochim. Biophys. Acta Biomembr. 1068 1991 133 141
14. Y. Matsumura, and H. Maeda A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent Smancs Cancer Res. 46 1986 6387 6392 (Pubitemid 17221789)
15. A. Gabizon, and D. Papahadjopoulos Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors Proc. Natl. Acad. Sci. U. S. A. 85 1988 6949 6953
16. A. Gabizon, and D. Papahadjopoulos The role of surface charge and hydrophilic groups on liposome clearance in vivo Biochim. Biophys. Acta Biomembr. 1103 1992 94 100
17. A. Abuchowski, T. van Es, N.C. Palczuk, and F.F. Davis Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol J. Biol. Chem. 252 1977 3578 3581 (Pubitemid 8116087)
18. M.C. Woodle, and D.D. Lasic Sterically stabilized liposomes Biochim. Biophys. Acta Rev. Biomembr. 1113 1992 171 199
19. A. Gabizon, R. Isacson, E. Libson, B. Kaufman, B. Uziely, and R. Catane et al. Clinical studies of liposome-encapsulated doxorubicin Acta Oncol. 33 1994 779 786 (Pubitemid 24380309)
20. H.-I. Chang, and M.-K. Yeh Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy Int. J. Nanomedicine 7 2012 49 60
21. Y. Barenholz Doxil(r) - the first FDA-approved nano-drug: lessons learned J. Control. Release 160 2012 117 134
22. D. Needham, T.J. McIntosh, and D.V. Zhelev Surface chemistry of the sterically stabilized PEG-liposome: general principles J. AS, Liposomes: Rational Design 1999 Marcel Dekker Inc. New York 13 62
23. E. Evans, D.J. Klingenberg, W. Rawicz, and F. Szoka Interactions between polymer-grafted membranes in concentrated solutions of free polymer Langmuir 12 1996 3031 3037 (Pubitemid 126567885)
24. A.S. Abu Lila, H. Kiwada, and T. Ishida The accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manage J. Control. Release 172 2013 38 47
25. E.T. Dams, P. Laverman, W.J. Oyen, G. Storm, G.L. Scherphof, and J.W. van Der Meer et al. Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes J. Pharmacol. Exp. Ther. 292 2000 1071 1079 (Pubitemid 30136603)
26. T. Ishida, X. Wang, T. Shimizu, K. Nawata, and H. Kiwada PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner J. Control. Release 122 2007 349 355 (Pubitemid 47407760)
27. R. Duncan, and M.J. Vicent Do HPMA copolymer conjugates have a future as clinically useful nanomedicines? A critical overview of current status and future opportunities Adv. Drug Deliv. Rev. 62 2010 272 282
28. R. Duncan Development of HPMA copolymer-anticancer conjugates: clinical experience and lessons learnt Adv. Drug Deliv. Rev. 61 2009 1131 1148
29. T. Etrych, L. Kovář, J. Strohalm, P. Chytil, B. Říhová, and K. Ulbrich Biodegradable star HPMA polymer-drug conjugates: biodegradability, distribution and anti-tumor efficacy J. Control. Release 154 2011 241 248
30. M.L. Immordino, F. Dosio, and L. Cattel Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential Int. J. Nanomedicine 1 2006 297 315
31. A.N. Zelikin, G.K. Such, A. Postma, and F. Caruso Poly(vinylpyrrolidone) for bioconjugation and surface ligand immobilization Biomacromolecules 8 2007 2950 2953 (Pubitemid 47516950)
32. F.C. Gaertner, R. Luxenhofer, B. Blechert, R. Jordan, and M. Essler Synthesis, biodistribution and excretion of radiolabeled poly(2-alkyl-2- oxazoline)s J. Control. Release 119 2007 291 300 (Pubitemid 46770877)
33. S. Zalipsky, C.B. Hansen, J.M. Oaks, and T.M. Allen Evaluation of blood clearance rates and biodistribution of poly(2-oxazoline)-grafted liposomes J. Pharm. Sci. 85 1996 133 137
34. V.P. Torchilin, V.S. Trubetskoy, K.R. Whiteman, P. Caliceti, P. Ferruti, and F.M. Veronese New synthetic amphiphilic polymers for steric protection of liposomes in vivo J. Pharm. Sci. 84 1995 1049 1053
35. S. Drotleff, U. Lungwitz, M. Breunig, A. Dennis, T. Blunk, and J. Teßmar et al. Biomimetic polymers in pharmaceutical and biomedical sciences Eur. J. Pharm. Biopharm. 58 2004 385 407 (Pubitemid 39037243)
36. V.P. Torchilin, M.I. Shtilman, V.S. Trubetskoy, K. Whiteman, and A.M. Milstein Amphiphilic vinyl polymers effectively prolong liposome circulation time in vivo Biochim. Biophys. Acta Biomembr. 1195 1994 181 184 (Pubitemid 24318108)
37. K. Maruyama, S. Okuizumi, O. Ishida, H. Yamauchi, H. Kikuchi, and M. Iwatsuru Phosphatidyl polyglycerols prolong liposome circulation in vivo Int. J. Pharm. 111 1994 103 107 (Pubitemid 24277384)
38. A.S. Abu Lila, K. Nawata, T. Shimizu, T. Ishida, and H. Kiwada Use of polyglycerol (PG), instead of polyethylene glycol (PEG), prevents induction of the accelerated blood clearance phenomenon against long-circulating liposomes upon repeated administration Int. J. Pharm. 456 2013 235 242
39. Y. Kaneda, Y. Tsutsumi, Y. Yoshioka, H. Kamada, Y. Yamamoto, and H. Kodaira et al. The use of PVP as a polymeric carrier to improve the plasma half-life of drugs Biomaterials 25 2004 3259 3266 (Pubitemid 38234786)
40. H. Takeuchi, H. Kojima, T. Toyoda, H. Yamamoto, T. Hino, and Y. Kawashima Prolonged circulation time of doxorubicin-loaded liposomes coated with a modified polyvinyl alcohol after intravenous injection in rats Eur. J. Pharm. Biopharm. 48 1999 123 129 (Pubitemid 29401988)
41. H. Takeuchi, H. Kojima, H. Yamamoto, and Y. Kawashima Evaluation of circulation profiles of liposomes coated with hydrophilic polymers having different molecular weights in rats J. Control. Release 75 2001 83 91 (Pubitemid 32635199)
42. E. Roux, R. Stomp, S. Giasson, M. Pézolet, P. Moreau, and J.-C. Leroux Steric stabilization of liposomes by pH-responsive N-isopropylacrylamide copolymer J. Pharm. Sci. 91 2002 1795 1802 (Pubitemid 34810524)
43. E.L. Riché, B.W. Erickson, and M.J. Cho Novel long-circulating liposomes containing peptide library-lipid conjugates: synthesis and in vivo behavior J. Drug Target. 12 2004 355 361 (Pubitemid 39294833)
44. B. Romberg, J.M. Metselaar, L. Baranyi, C.J. Snel, R. Bünger, and W.E. Hennink et al. Poly(amino acid)s: promising enzymatically degradable stealth coatings for liposomes Int. J. Pharm. 331 2007 186 189 (Pubitemid 46223617)
45. B. Romberg, C. Oussoren, C.J. Snel, W.E. Hennink, and G. Storm Effect of liposome characteristics and dose on the pharmacokinetics of liposomes coated with poly(amino acid)s Pharm. Res. 24 2007 2394 2401 (Pubitemid 350060711)
46. J.M. Metselaar, P. Bruin, L.W.T. de Boer, T. de Vringer, C. Snel, and C. Oussoren et al. A novel family of l-amino acid-based biodegradable polymer-lipid conjugates for the development of long-circulating liposomes with effective drug-targeting capacity Bioconjug. Chem. 14 2003 1156 1164 (Pubitemid 37449043)
47. M.C. Woodle, C.M. Engbers, and S. Zalipsky New amphipathic polymer-lipid conjugates forming long-circulating reticuloendothelial system-evading liposomes Bioconjug. Chem. 5 1994 493 496
48. K.R. Whiteman, V. Subr, K. Ulbrich, and V.P. Torchilin Poly(Hpma)-coated liposomes demonstrate prolonged circulation in mice J. Liposome Res. 11 2001 153 164 (Pubitemid 33096375)
49. T.M. Allen, C. Hansen, F. Martin, C. Redemann, and A. Yau-Young Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo Biochim. Biophys. Acta 1066 1991 29 36
50. R.-L. Hong, C.-J. Huang, Y.-L. Tseng, V.F. Pang, S.-T. Chen, and J.-J. Liu et al. Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial? Clin. Cancer Res. 5 1999 3645 3652
51. P.L. Rodriguez, T. Harada, D.A. Christian, D.A. Pantano, R.K. Tsai, and D.E. Discher Minimal "Self" peptides that inhibit phagocytic clearance and enhance delivery of nanoparticles Science 339 2013 971 975
52. C.-M.J. Hu, R.H. Fang, J. Copp, B.T. Luk, and L. Zhang A biomimetic nanosponge that absorbs pore-forming toxins Nat. Nanotechnol. 8 2013 336 340
53. J.J. Moon, B. Huang, and D.J. Irvine Engineering nano- and microparticles to tune immunity Adv. Mater. 24 2012 3724 3746
54. W. Jiskoot, R.M.F. van Schie, M.G. Carstens, and H. Schellekens Immunological risk of injectable drug delivery systems Pharm. Res. 26 2009 1303 1314
55. D.S. Watson, A.N. Endsley, and L. Huang Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens Vaccine 30 2012 2256 2272
56. W.H. Kutteh, and C.D. Hinote Antiphospholipid antibody syndrome Obstet. Gynecol. Clin. N. Am. 41 2014 113 132
57. B. Říhová Immunomodulating activities of soluble synthetic polymer-bound drugs Adv. Drug Deliv. Rev. 54 2002 653 674 (Pubitemid 35247521)
58. K. Uemura, R.A. Nicolotti, H.R. Six, and S.C. Kinsky Antibody formation in response to liposomal model membranes sensitized with N-substituted phosphatidylethanolamine derivatives Biochemistry 13 1974 1572 1578
59. B. Babbit, L. Burtis, P. Dentinger, P. Constantinides, L. Hillis, and B. McGirl et al. Contact-dependent, immune complex-mediated lysis of hapten-sensitized liposomes Bioconjug. Chem. 4 1993 199 205
60. W.M. Li, M.B. Bally, and M.P. Schutze-Redelmeier Enhanced immune response to T-independent antigen by using CpG oligodeoxynucleotides encapsulated in liposomes Vaccine 20 2001 148 157 (Pubitemid 32905327)
61. P. Brûlet, and H.M. McConnell Lateral hapten mobility and immunochemistry of model membranes Proc. Natl. Acad. Sci. U. S. A. 73 1976 2977 2981
62. K. Kimura, Y. Arata, T. Yasuda, K. Kinosita, and M. Nakanishi Location of membrane-bound hapten with different length spacers Immunology 69 1990 323 328 (Pubitemid 20076506)
63. O.D. Hendrickson, A.V. Zherdev, A.P. Kaplun, and B.B. Dzantiev Experimental study and mathematical modeling of the interaction between antibodies and antigens on the surface of liposomes Mol. Immunol. 39 2002 413 422 (Pubitemid 35284409)
64. L.D. Leserman, J.N. Weinstein, J.J. Moore, and W.D. Terry Specific interaction of myeloma tumor cells with hapten-bearing liposomes containing methotrexate and carboxyfluorescein Cancer Res. 40 1980 4768 4774 (Pubitemid 11199752)
65. A.J. van Houte, H. Snippe, and J.M. Willers Characterization of immunogenic properties of haptenated liposomal model membranes in mice. IV. Induction of IgM memory Immunology 43 1981 627 634 (Pubitemid 11040029)
66. S. Günther, D. Hempel, M. Dunkel, K. Rother, and R. Preissner SuperHapten: a comprehensive database for small immunogenic compounds Nucleic Acids Res. 35 2007 D906 D910
67. B.G. Schuster, M. Neidig, B.M. Alving, and C.R. Alving Production of antibodies against phosphocholine, phosphatidylcholine, sphingomyelin, and lipid A by injection of liposomes containing lipid A J. Immunol. 122 1979 900 905 (Pubitemid 9146016)
68. G.R. Matyas, N.M. Wassef, M. Rao, and C.R. Alving Induction and detection of antibodies to squalene J. Immunol. Methods 245 2000 1 14
69. J.A. Haxby, C.B. Kinsky, and S.C. Kinsky Immune response of a liposomal model membrane Proc. Natl. Acad. Sci. U. S. A. 61 1968 300 307
70. G.R. Matyas, and C.R. Alving Antigen-specific enhancement of natural human IgG antibodies to phosphatidylcholine, phosphatidylglycerol, phosphatidylinositol-4-phosphate, cholesterol, and lipid A by a liposomal vaccine containing lipid A Vaccine 29 2011 5137 5144
71. K.S.M. Phillipps, M.N. Wykes, X.Q. Liu, M. Brown, J. Blanchfield, and I. Toth A novel synthetic adjuvant enhances dendritic cell function Immunology 128 2009 e582 e588
72. P. Moyle, and I. Toth Self-adjuvanting lipopeptide vaccines Curr. Med. Chem. 15 2008 506 516 (Pubitemid 351472417)
73. P. Harmon, D. Cabral-Lilly, R.A. Reed, F.P. Maurio, J.C. Franklin, and A. Janoff The release and detection of endotoxin from liposomes Anal. Biochem. 250 1997 139 146 (Pubitemid 27319088)
74. V.J. Venditto, and F.C. Szoka Cancer nanomedicines: so many papers and so few drugs! Adv. Drug Deliv. Rev. 65 2013 80 88
75. T. Ishida, K. Atobe, X. Wang, and H. Kiwada Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin- encapsulation and high-dose first injection J. Control. Release 115 2006 251 258 (Pubitemid 44634849)
76. H. Koide, T. Asai, K. Hatanaka, S. Akai, T. Ishii, and E. Kenjo et al. T cell-independent B cell response is responsible for ABC phenomenon induced by repeated injection of PEGylated liposomes Int. J. Pharm. 392 2010 218 223
77. C. Li, J. Cao, Y. Wang, X. Zhao, C. Deng, and N. Wei et al. Accelerated blood clearance of pegylated liposomal topotecan: Influence of polyethylene glycol grafting density and animal species J. Pharm. Sci. 101 2012 3864 3876
78. P. Laverman, M.G. Carstens, O.C. Boerman, E.T. Dams, W.J. Oyen, and N. Van Rooijen et al. Factors affecting the accelerated blood clearance of polyethylene glycol-liposomes upon repeated injection J. Pharmacol. Exp. Ther. 298 2001 607 612 (Pubitemid 32673411)
79. G.J. Charrois, and T.M. Allen Multiple injections of PEGylated liposomal doxorubicin: pharmacokinetics and therapeutic activity J. Pharmacol. Exp. Ther. 306 2003 1058 1067 (Pubitemid 37025314)
80. J. Cui, C. Li, C. Wang, Y. Li, L. Zhang, and L. Zhang et al. Repeated injection of PEGylated liposomal antitumour drugs induces the disappearance of the rapid distribution phase J. Pharm. Pharmacol. 60 2008 1651 1657
81. P.N. Shek, and T.D. Heath Immune response mediated by liposome-associated protein antigens. III. Immunogenicity of bovine serum albumin covalently coupled to vesicle surface Immunology 50 1983 101 106 (Pubitemid 13039863)
82. P.N. Shek, N.G. Lopez, and T.D. Heath Immune response mediated by liposome-associated protein antigens. IV. Modulation of antibody formation by vesicle-encapsulated methotrexate Immunology 57 1986 153 157 (Pubitemid 16232231)
83. P.G. Tardi, E.N. Swartz, T.O. Harasym, P.R. Cullis, and M.B. Bally An immune response to ovalbumin covalently coupled to liposomes is prevented when the liposomes used contain doxorubicin J. Immunol. Methods 210 1997 137 148 (Pubitemid 28266558)
84. C. Oja, P. Tardi, M.P. Schutze-Redelmeier, and P.R. Cullis Doxorubicin entrapped within liposome-associated antigens results in a selective inhibition of the antibody response to the linked antigen Biochim. Biophys. Acta 1468 2000 31 40
85. K. Ichikawa, T. Asai, K. Shimizu, S. Yonezawa, T. Urakami, and H. Miyauchi et al. Suppression of immune response by antigen-modified liposomes encapsulating model agents: a novel strategy for the treatment of allergy J. Control. Release 167 2013 284 289
86. K. Yasuhara, T. Kawataki, S. Okuda, S. Oshima, and J.-I. Kikuchi Spontaneously formed semipermeable organic-inorganic hybrid vesicles permitting molecular weight selective transmembrane passage Chem. Commun. (Camb.) 49 2013 665 667
87. S. Khiati, D. Luvino, K. Oumzil, B. Chauffert, M. Camplo, and P. Barthélémy Nucleoside-lipid-based nanoparticles for cisplatin delivery ACS Nano 5 2011 8649 8655
88. A. Gissot, M. Camplo, M.W. Grinstaff, and P. Barthélémy Nucleoside, nucleotide and oligonucleotide based amphiphiles: a successful marriage of nucleic acids with lipids Org. Biomol. Chem. 6 2008 1324 1333 (Pubitemid 351469849)
89. Y. Singh, P. Murat, and E. Defrancq Recent developments in oligonucleotide conjugation Chem. Soc. Rev. 39 2010 2054 2070
90. C. Ceballos, C.A.H. Prata, S. Giorgio, F. Garzino, D. Payet, and P. Barthélémy et al. Cationic nucleoside lipids based on a 3-nitropyrrole universal base for siRNA delivery Bioconjug. Chem. 20 2009 193 196
91. C. Ceballos, S. Khiati, C.A.H. Prata, X.-X. Zhang, S. Giorgio, and P. Marsal et al. Cationic nucleoside lipids derived from universal bases: a rational approach for siRNA transfection Bioconjug. Chem. 21 2010 1062 1069
92. V. Allain, C. Bourgaux, and P. Couvreur Self-assembled nucleolipids: from supramolecular structure to soft nucleic acid and drug delivery devices Nucleic Acids Res. 40 2012 1891 1903
93. N. Taib, A. Aimé, S. Houmadi, S. Castano, P. Barthé lémy, and M. Laguerre et al. Chemical details on nucleolipid supramolecular architecture: molecular modeling and physicochemical studies Langmuir 28 2012 7452 7460
94. P. Chabaud, M. Camplo, D. Payet, G. Serin, L. Moreau, and P. Barthélémy et al. Cationic nucleoside lipids for gene delivery Bioconjug. Chem. 17 2006 466 472
95. M. Banchelli, D. Berti, and P. Baglioni Molecular recognition drives oligonucleotide binding to nucleolipid self-assemblies Angew. Chem. Int. Ed. Engl. 46 2007 3070 3073 (Pubitemid 46973520)
96. S. Khiati, N. Pierre, S. Andriamanarivo, M.W. Grinstaff, N. Arazam, and F. Nallet et al. Anionic nucleotide-lipids for in vitro DNA transfection Bioconjug. Chem. 20 2009 1765 1772
97. M. Ma, Y. Gong, and D. Bong Lipid membrane adhesion and fusion driven by designed, minimally multivalent hydrogen-bonding lipids J. Am. Chem. Soc. 131 2009 16919 16926
98. M. Ma, A. Paredes, and D. Bong Intra- and intermembrane pairwise molecular recognition between synthetic hydrogen-bonding phospholipids J. Am. Chem. Soc. 130 2008 14456 14458
99. A. Polidori, N. Michel, A.S. Fabiano, and B. Pucci Exotic aqueous behavior of synthetic lipids: formation of vesicular nanotubes Chem. Phys. Lipids 136 2005 23 46 (Pubitemid 40835996)
100. G. Godeau, and P. Barthélémy Glycosyl-nucleoside lipids as low-molecular-weight gelators Langmuir 25 2009 8447 8450
101. G. Godeau, J. Bernard, C. Staedel, and P. Barthélémy Glycosyl-nucleoside-lipid based supramolecular assembly as a nanostructured material with nucleic acid delivery capabilities Chem. Commun. 2009 5127 5129
102. S.C. Semple, T.O. Harasym, K.A. Clow, S.M. Ansell, S.K. Klimuk, and M.J. Hope Immunogenicity and rapid blood clearance of liposomes containing polyethylene glycol-lipid conjugates and nucleic acid J. Pharmacol. Exp. Ther. 312 2005 1020 1026 (Pubitemid 40293760)
103. L. Nobs, F. Buchegger, R. Gurny, and E. All mann Current methods for attaching targeting ligands to liposomes and nanoparticles J. Pharm. Sci. 93 2004 1980 1992 (Pubitemid 39045480)
104. A.S. Manjappa, K.R. Chaudhari, M.P. Venkataraju, P. Dantuluri, B. Nanda, and C. Sidda et al. Antibody derivatization and conjugation strategies: application in preparation of stealth immunoliposome to target chemotherapeutics to tumor J. Control. Release 150 2011 2 22
105. F.J. Martin, and D. Papahadjopoulos Irreversible coupling of immunoglobulin fragments to preformed vesicles. An improved method for liposome targeting J. Biol. Chem. 257 1982 286 288 (Pubitemid 12109779)
106. J.-P. Colletier, B. Chaize, M. Winterhalter, and D. Fournier Protein encapsulation in liposomes: efficiency depends on interactions between protein and phospholipid bilayer BMC Biotechnol. 2 2002 9
107. L. Illum, P.D. Jones, R.W. Baldwin, and S.S. Davis Tissue distribution of poly(hexyl 2-cyanoacrylate) nanoparticles coated with monoclonal antibodies in mice bearing human tumor xenografts J. Pharmacol. Exp. Ther. 230 1984 733 736 (Pubitemid 14040397)
108. Z. Huang, J.I. Park, D.S. Watson, P. Hwang, and F.C. Szoka Facile synthesis of multivalent nitrilotriacetic acid (NTA) and NTA conjugates for analytical and drug delivery applications Bioconjug. Chem. 17 2006 1592 1600 (Pubitemid 44851506)
109. C.L. van Broekhoven, and J.G. Altin The novel chelator lipid 3(nitrilotriacetic acid)-ditetradecylamine (NTA(3)-DTDA) promotes stable binding of His-tagged proteins to liposomal membranes: potent anti-tumor responses induced by simultaneously targeting antigen, cytokine and costimulatory signals to T cells Biochim. Biophys. Acta 1716 2005 104 116 (Pubitemid 41532288)
110. G. Chikh Attaching histidine-tagged peptides and proteins to lipid-based carriers through use of metal-ion-chelating lipids Biochim. Biophys. Acta Biomembr. 1567 2002 204 212 (Pubitemid 35454062)
111. R. Rüger, D. Müller, A. Fahr, and R.E. Kontermann In vitro characterization of binding and stability of single-chain Fv Ni-NTA-liposomes J. Drug Target. 14 2006 576 582 (Pubitemid 44592891)
112. N.O. Fischer, C.D. Blanchette, B.A. Chromy, E.A. Kuhn, B.W. Segelke, and M. Corzett et al. Immobilization of His-tagged proteins on nickel-chelating nanolipoprotein particles Bioconjug. Chem. 20 2009 460 465
113. G.B. Sigal, C. Bamdad, A. Barberis, J. Strominger, and G.M. Whitesides A self-assembled monolayer for the binding and study of histidine-tagged proteins by surface plasmon resonance Anal. Chem. 68 1996 490 497
114. J.G. Altin, M.G. Banwell, P.A. Coghlan, C.J. Easton, M.R. Nairn, and D.A. Offermann Synthesis of NTA 3-DTDA - a chelator-lipid that promotes stable binding of His-tagged proteins to membranes Aust. J. Chem. 59 2006 302 306 (Pubitemid 43877055)
115. C.L. van Broekhoven, and J.G. Altin The novel chelator lipid 3 (nitrilotriacetic acid)-ditetradecylamine (NTA 3-DTDA) promotes stable binding of His-tagged proteins to liposomal membranes: potent anti-tumor responses induced by simultaneously targeting antigen, cytokine and costimulatory signals to T cells Biochim. Biophys. Acta Biomembr. 1716 2005 104 116 (Pubitemid 41532288)
116. Z. Huang, P. Hwang, D.S. Watson, L. Cao, and F.C. Szoka Tris-nitrilotriacetic acids of subnanomolar affinity toward hexahistidine tagged molecules Bioconjug. Chem. 20 2009 1667 1672
117. V. Platt, Z. Huang, L. Cao, M. Tiffany, K. Riviere, and F.C. Szoka Influence of multivalent nitrilotriacetic acid lipid-ligand affinity on the circulation half-life in mice of a liposome-attached His6-protein Bioconjug. Chem. 21 2010 892 902
118. D.S. Watson, V.M. Platt, L. Cao, V.J. Venditto, and F.C. Szoka Antibody response to polyhistidine-tagged peptide and protein antigens attached to liposomes via lipid-linked nitrilotriacetic acid in mice Clin. Vaccine Immunol. 18 2011 289 297
119. U.B. Nielsen, D.B. Kirpotin, E.M. Pickering, D.C. Drummond, and J.D. Marks A novel assay for monitoring internalization of nanocarrier coupled antibodies BMC Immunol. 7 2006 24 39
120. V.P. Torchilin, and V. Weissig Liposomes: A Practical Approach 2003 Oxford University Press
121. R.R.C. New Liposomes: A Practical Approach 1990 Oxford University Press USA
122. D.C. Drummond, C.O. Noble, M.E. Hayes, J.W. Park, and D.B. Kirpotin Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development J. Pharm. Sci. 97 2008 4696 4740
123. S. Mabrey, P.L. Mateo, and J.M. Sturtevant High-sensitivity scanning calorimetric study of mixtures of cholesterol with dimyristoyl- and dipalmitoylphosphatidylcholines Biochemistry 17 1978 2464 2468 (Pubitemid 8365774)
124. T.P. McMullen, R.N. Lewis, and R.N. McElhaney Differential scanning calorimetric study of the effect of cholesterol on the thermotropic phase behavior of a homologous series of linear saturated phosphatidylcholines Biochemistry 32 1993 516 522 (Pubitemid 23034888)
125. R.A. Demel, K.R. Bruckdorfer, and L.L.M. Van Deenen The effect of sterol structure on the permeability of lipomes to glucose, glycerol and Rb Biochim. Biophys. Acta Biomembr. 255 1972 321 330
126. D. Papahadjopoulos, S. Nir, and S. Oki Permeability properties of phospholipid membranes: effect of cholesterol and temperature Biochim. Biophys. Acta 266 1972 561 583
127. V.P. Torchilin Recent advances with liposomes as pharmaceutical carriers Nat. Rev. Drug Discov. 4 2005 145 160 (Pubitemid 40282557)
128. D. Bach Phospholipid/cholesterol model membranes: formation of cholesterol crystallites Biochim. Biophys. Acta Biomembr. 1610 2003 187 197 (Pubitemid 36324463)
129. M.C. Phillips, W.J. Johnson, and G.H. Rothblat Mechanisms and consequences of cellular cholesterol exchange and transfer Biochim. Biophys. Acta Rev. Biomembr. 906 1987 223 276
130. J.A. Hamilton Fast flip-flop of cholesterol and fatty acids in membranes: implications for membrane transport proteins Curr. Opin. Lipidol. 14 2003 263 271 (Pubitemid 36688205)
131. C.C. Kan, J. Yan, and R. Bittman Rates of spontaneous exchange of synthetic radiolabeled sterols between lipid vesicles Biochemistry 31 1992 1866 1874
132. J. Ding, A.P. Starling, J.M. East, and A.G. Lee Binding sites for cholesterol on Ca(2 +)-ATPase studied by using a cholesterol-containing phospholipid Biochemistry 33 1994 4974 4979 (Pubitemid 24158449)
133. Z. Huang, M.R. Jaafari, and F.C. Szoka Disterolphospholipids: nonexchangeable lipids and their application to liposomal drug delivery Angew. Chem. Int. Ed. Engl. 48 2009 4146 4149
134. Z. Huang, and F.C. Szoka Sterol-modified phospholipids: cholesterol and phospholipid chimeras with improved biomembrane properties J. Am. Chem. Soc. 130 2008 15702 15712
135. A.G. Kohli, H.M. Kieler-Ferguson, D. Chan, and F.C. Szoka A robust and quantitative method for tracking liposome contents after intravenous administration J. Control. Release 176 2014 86 93
136. J.F. Lovell, C.S. Jin, E. Huynh, H. Jin, C. Kim, and J.L. Rubinstein et al. Porphysome nanovesicles generated by porphyrin bilayers for use as multimodal biophotonic contrast agents Nat. Mater. 10 2011 324 332
137. M.M. Fretz, A. Høgset, G.A. Koning, W. Jiskoot, and G. Storm Cytosolic delivery of liposomally targeted proteins induced by photochemical internalization Pharm. Res. 24 2007 2040 2047 (Pubitemid 47493573)
138. K.K. Ng, J.F. Lovell, A. Vedadi, T. Hajian, and G. Zheng Self-assembled porphyrin nanodiscs with structure-dependent activation for phototherapy and photodiagnostic applications ACS Nano 7 2013 3484 3490
139. E. Huynh, J.F. Lovell, B.L. Helfield, M. Jeon, C. Kim, and D.E. Goertz et al. Porphyrin shell microbubbles with intrinsic ultrasound and photoacoustic properties J. Am. Chem. Soc. 134 2012 16464 16467
140. D.W. Tondo, E.C. Leopoldino, B.S. Souza, G.A. Micke, A.C.O. Costa, and H.D. Fiedler et al. Synthesis of a new zwitterionic surfactant containing an imidazolium ring. Evaluating the chameleon-like behavior of zwitterionic micelles Langmuir 26 2010 15754 15760
141. D. Papahadjopoulos, S. Nir, and N. Düzgünes Molecular mechanisms of calcium-induced membrane fusion J. Bioenerg. Biomembr. 22 1990 157 179 (Pubitemid 20144511)
142. E.K. Perttu, and F.C. Szoka Zwitterionic sulfobetaine lipids that form vesicles with salt-dependent thermotropic properties Chem. Commun. (Camb.) 47 2011 12613 12615
143. E.K. Perttu, A.G. Kohli, and F.C. Szoka Jr. Inverse-phosphocholine lipids: a remix of a common phospholipid J. Am. Chem. Soc. 134 2012 4485 4488
144. A.G. Kohli, C.L. Walsh, and F.C. Szoka Synthesis and characterization of betaine-like diacyl lipids: zwitterionic lipids with the cationic amine at the bilayer interface Chem. Phys. Lipids 165 2012 252 259
145. E.S. Kim, C. Lu, F.R. Khuri, M. Tonda, B.S. Glisson, and D. Liu et al. A phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer Lung Cancer 34 2001 427 432 (Pubitemid 33041478)
146. T.M. Allen, and P.R. Cullis Liposomal drug delivery systems: from concept to clinical applications Adv. Drug Deliv. Rev. 65 2013 36 48
147. S. Bibi, E. Lattmann, A.R. Mohammed, and Y. Perrie Trigger release liposome systems: local and remote controlled delivery? J. Microencapsul. 29 2012 262 276
148. J.K. Mills, and D. Needham Lysolipid incorporation in dipalmitoylphosphatidylcholine bilayer membranes enhances the ion permeability and drug release rates at the membrane phase transition Biochim. Biophys. Acta 1716 2005 77 96 (Pubitemid 41532286)
149. D. Needham, J.-Y. Park, A.M. Wright, and J. Tong Materials characterization of the low temperature sensitive liposome (LTSL): effects of the lipid composition (lysolipid and DSPE-PEG2000) on the thermal transition and release of doxorubicin Faraday Discuss. 161 2013 515 534
150. F. Kratz DOXO-EMCH (INNO-206): the first albumin-binding prodrug of doxorubicin to enter clinical trials Expert Opin. Investig. Drugs 16 2007 855 866 (Pubitemid 46882358)
151. Y. Wang, L. Li, W. Jiang, Z. Yang, and Z. Zhang Synthesis and preliminary antitumor activity evaluation of a DHA and doxorubicin conjugate Bioorg. Med. Chem. Lett. 16 2006 2974 2977
152. N. Duhem, F. Danhier, V. Pourcelle, J.-M. Schumers, O. Bertrand, and C.S. Leduff et al. Self-assembling doxorubicin-tocopherol succinate prodrug as a new drug delivery system: synthesis, characterization, and in vitro and in vivo anticancer activity Bioconjug. Chem. 25 2013 72 81
153. J. Verweij, and H.M. Pinedo Mitomycin C: mechanism of action, usefulness and limitations Anticancer Drugs 1 1990 5 13
154. A.A. Gabizon, D. Tzemach, A.T. Horowitz, H. Shmeeda, J. Yeh, and S. Zalipsky Reduced toxicity and superior therapeutic activity of a mitomycin C lipid-based prodrug incorporated in PEGylated liposomes Clin. Cancer Res. 12 2006 1913 1920
155. A. Gabizon, Y. Amitay, D. Tzemach, J. Gorin, H. Shmeeda, and S. Zalipsky Therapeutic efficacy of a lipid-based prodrug of mitomycin C in PEGylated liposomes: studies with human gastro-entero-pancreatic ectopic tumor models J. Control. Release 160 2012 245 253
156. E. Moysan, G. Bastiat, and J.-P. Benoit Gemcitabine versus modified gemcitabine: a review of several promising chemical modifications Mol. Pharm. 10 2013 430 444
157. A.D. Adema, N. Losekoot, K. Smid, I. Kathmann, F. Myhren, and M.L. Sandvold et al. Induction of resistance to the lipophilic cytarabine prodrug elacytarabine (CP-4055) in CEM leukemic cells Nucleosides Nucleotides Nucleic Acids 29 2010 394 399
158. K. Breistøl, J. Balzarini, M.L. Sandvold, F. Myhren, M. Martinsen, and E. De Clercq et al. Antitumor activity of P-4055 (elaidic acid-cytarabine) compared to cytarabine in metastatic and s.c. human tumor xenograft models Cancer Res. 59 1999 2944 2949 (Pubitemid 29283136)
159. F.E. Stuurman, E.E. Voest, A. Awada, P.O. Witteveen, T. Bergeland, and P.A. Hals et al. Phase I study of oral CP-4126, a gemcitabine derivative, in patients with advanced solid tumors Invest. New Drugs 31 2013 959 966
160. M.O. Bradley, N.L. Webb, F.H. Anthony, P. Devanesan, P.A. Witman, and S. Hemamalini et al. Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel Clin. Cancer Res. 7 2001 3229 3238 (Pubitemid 32963848)
161. R.J. Jones, R.E. Hawkins, M.M. Eatock, D.R. Ferry, F.A.L.M. Eskens, and H. Wilke et al. A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma Cancer Chemother. Pharmacol. 61 2007 435 441 (Pubitemid 350275978)
162. A.Y. Bedikian, R.C. DeConti, R. Conry, S. Agarwala, N. Papadopoulos, and K.B. Kim et al. Phase 3 study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic malignant melanoma Ann. Oncol. 22 2011 787 793
163. F. Dosio, L.H. Reddy, A. Ferrero, B. Stella, L. Cattel, and P. Couvreur Novel nanoassemblies composed of squalenoyl-paclitaxel derivatives: synthesis, characterization, and biological evaluation Bioconjug. Chem. 21 2010 1349 1361
164. J.L. Arias, L.H. Reddy, and P. Couvreur Magnetoresponsive squalenoyl gemcitabine composite nanoparticles for cancer active targeting Langmuir 24 2008 7512 7519
165. J.L. Arias, L.H. Reddy, M. Othman, B. Gillet, D. Desmaële, and F. Zouhiri et al. Squalene based nanocomposites: a new platform for the design of multifunctional pharmaceutical theragnostics ACS Nano 5 2011 1513 1521
166. Z. Cheng, A. Al Zaki, J.Z. Hui, V.R. Muzykantov, and A. Tsourkas Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities